The portfolio maintains a sizable cost advantage over competitors, priced within the least expensive fee quintile among peers.
iShares Neuroscience and Healthcare ETF IBRN
Morningstar’s Analysis IBRN
Will IBRN outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 42.1
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Sarepta Therapeutics Inc | 4.93 | 172,555 | Healthcare |
argenx SE ADR | 4.60 | 161,057 | Healthcare |
Dyne Therapeutics Inc Ordinary Shares | 4.37 | 153,166 | Healthcare |
ACADIA Pharmaceuticals Inc | 4.16 | 145,548 | Healthcare |
Neurocrine Biosciences Inc | 4.07 | 142,377 | Healthcare |
Alkermes PLC | 4.02 | 140,873 | Healthcare |
Intra-Cellular Therapies Inc | 4.01 | 140,350 | Healthcare |
Cerevel Therapeutics Holdings Inc Ordinary Shares | 4.00 | 139,962 | Healthcare |
Axonics Inc | 4.00 | 139,901 | Healthcare |
Biohaven Ltd | 3.99 | 139,620 | Healthcare |